BridgeBio Pharma Gross Margin 2018-2026 | BBIO
Current and historical gross margin for BridgeBio Pharma (BBIO) over the last 10 years. The current gross profit margin for BridgeBio Pharma as of June 30, 2026 is %.
| BridgeBio Pharma Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2026-06-30 | $0.71B | $0.67B | 94.40% |
| 2026-03-31 | $0.58B | $0.55B | 95.01% |
| 2025-12-31 | $0.50B | $0.48B | 95.63% |
| 2025-09-30 | $0.36B | $0.34B | 95.49% |
| 2025-06-30 | $0.24B | $0.23B | 95.78% |
| 2025-03-31 | $0.13B | $0.12B | 95.31% |
| 2024-12-31 | $0.22B | $0.22B | 98.65% |
| 2024-09-30 | $0.22B | $0.22B | 99.08% |
| 2024-06-30 | $0.22B | $0.22B | 99.09% |
| 2024-03-31 | $0.22B | $0.22B | 98.63% |
| 2023-12-31 | $0.01B | $0.01B | 60.00% |
| 2023-09-30 | $0.01B | $0.01B | 60.00% |
| 2023-06-30 | $0.01B | $0.00B | 50.00% |
| 2023-03-31 | $0.08B | $0.08B | 96.15% |
| 2022-12-31 | $0.08B | $0.07B | 94.87% |
| 2022-09-30 | $0.09B | $0.08B | 94.38% |
| 2022-06-30 | $0.09B | $0.09B | 93.41% |
| 2022-03-31 | $0.07B | $0.07B | 92.96% |
| 2021-12-31 | $0.07B | $0.07B | 95.65% |
| 2021-09-30 | $0.06B | $0.06B | 98.21% |
| 2021-06-30 | $0.06B | $0.06B | 100.00% |
| 2020-09-30 | $0.02B | $0.02B | 100.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |